Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217

BACKGROUND: Recent advances in disease-modifying treatments highlight the need for accurately identifying individuals in early Alzheimer’s disease (AD) stages and for monitoring of treatment effects. Plasma measurements of phosphorylated tau (p-tau) are a promising biomarker for AD, but different as...

Descripción completa

Detalles Bibliográficos
Autores principales: Groot, Colin, Cicognola, Claudia, Bali, Divya, Triana-Baltzer, Gallen, Dage, Jeffrey L., Pontecorvo, Michael J., Kolb, Hartmuth C., Osssenkoppele, Rik, Janelidze, Shorena, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107269/
https://www.ncbi.nlm.nih.gov/pubmed/35568889
http://dx.doi.org/10.1186/s13195-022-01005-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107269/
https://www.ncbi.nlm.nih.gov/pubmed/35568889
http://dx.doi.org/10.1186/s13195-022-01005-8

Ejemplares similares